person · Reporting owner

FOEHR MATTHEW W

Disclosed activity across 5 companies

Tapewire entity: 53388
SEC CIK: 0001237556

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
FF EAI Robotics Ecosystem Inc.RTTR · Entity 7776	Director	January 21, 2020	April 23, 2020
OmniAb, Inc.OABI · Entity 5294	Director · President and CEO	April 07, 2026	April 08, 2026
Viking Therapeutics, Inc.VKTX · Entity 4067	Director	January 02, 2026	January 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

FF EAI Robotics Ecosystem Inc.

Report date January 21, 2020 · Filed April 23, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	138,635	Ending reported balance After 2020-04-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-01-21 · Conversion · Acquired 76,923 · Balance 100,174 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. Row 2 · 2020-04-10 · Grant · Acquired 38,461 · Balance 138,635 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.
Series B convertible preferred stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.30	Direct	0	Reported balance After 2020-01-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-21 · Conversion · Disposed 100 · Balance 0 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date.
Warrant Shares (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2023-11-05	Direct	0	Reported balance After 2020-04-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-04-10 · Disposition to issuer · Disposed 38,461 · Balance 0 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date.

F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.

OmniAb, Inc.

Report date April 07, 2026 · Filed April 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,420,492	Ending reported balance After 2026-04-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-04-07 · Exercise / conversion · Acquired 36,459 · Balance 4,439,736 F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-04-07 · Sale · Disposed 19,244 · Balance 4,420,492 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	309,376	Reported balance After 2026-04-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-07 · Exercise / conversion · Disposed 36,459 · Balance 309,376 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Viking Therapeutics, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.00001 per shareSEC Table I · non-derivative	Direct	135,186	Ending reported balance After 2026-01-02 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-01-02 · Exercise / conversion · Acquired 16,000 · Balance 148,036 Row 2 · 2026-01-02 · Sale · Disposed 16,000 · Balance 132,036 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2026-01-02 · Grant · Acquired 3,150 · Balance 135,186 F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2026-01-04	Direct	0	Reported balance After 2026-01-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-02 · Exercise / conversion · Disposed 16,000 · Balance 0
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2036-01-02	Direct	20,400	Reported balance After 2026-01-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-02 · Grant · Acquired 20,400 · Balance 20,400

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

LIGAND PHARMACEUTICALS INC

Report date November 01, 2022 · Filed November 04, 2022

Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	162,187	Reported balance After 2022-11-01 transaction · row 1 1 source row Row 1 · 2022-11-01 · Disposition to issuer · Disposed 20,304 · Balance 162,187 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-05-05	Direct	0	Reported balance After 2022-11-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-11-01 · Disposition to issuer · Disposed 34,214 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.

F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.

OmniAb Operations, Inc.

Report date November 01, 2022 · Filed November 04, 2022

Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	212,362	Reported balance After 2022-11-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-11-01 · Grant · Acquired 26,193 · Balance 212,362 F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-11-01 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2022-11-01 · Disposition to issuer · Disposed 212,362 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05	Direct	60,878	Reported balance After 2022-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-11-01 · Grant · Acquired 60,878 · Balance 60,878 F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05	Direct	0	Reported balance After 2022-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-11-01 · Disposition to issuer · Disposed 60,878 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $41.82 · Expires 2024-02-12	Direct	0	Reported balance After 2022-11-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-11-01 · Disposition to issuer · Disposed 55,222 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2025-02-10	Direct	0	Reported balance After 2022-11-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-11-01 · Disposition to issuer · Disposed 35,258 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.21 · Expires 2026-02-11	Direct	0	Reported balance After 2022-11-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-11-01 · Disposition to issuer · Disposed 22,660 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.41 · Expires 2027-02-24	Direct	0	Reported balance After 2022-11-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-11-01 · Disposition to issuer · Disposed 21,271 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $89.36 · Expires 2028-03-02	Direct	0	Reported balance After 2022-11-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-11-01 · Disposition to issuer · Disposed 17,711 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $66.30 · Expires 2029-02-11	Direct	0	Reported balance After 2022-11-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-11-01 · Disposition to issuer · Disposed 29,861 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $53.77 · Expires 2030-02-13	Direct	0	Reported balance After 2022-11-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-11-01 · Disposition to issuer · Disposed 29,012 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $99.75 · Expires 2031-02-03	Direct	0	Reported balance After 2022-11-01 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-11-01 · Disposition to issuer · Disposed 11,475 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.

F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.

F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.

F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.

F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.

F6: The stock option is fully vested and exercisable.

F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.

F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.

F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 03, 2021 Filed Feb 5, 2021 22:03 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantEmployee Stock Option (right to buy) · Derivative	13,136	$0.00 Strike: $177.50	$0.00	Disclosure SEC source: 0000886163-21-000029 · edgardoc.xml · derivative · entry 7 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,136 Underlying: Common Stock · 13,136 shares Expires 2031-02-03 F4 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/03/2021. Read SEC document
February 03, 2021 Filed Feb 5, 2021 22:03 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	6,595	$0.00	$0.00	Disclosure SEC source: 0000886163-21-000029 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,198 Read SEC document
January 25, 2021 Filed Jan 28, 2021 00:03 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	2,272	$156.01	$354,454.72	Disclosure SEC source: 0000886163-21-000015 · edgardoc.xml · nonDerivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,603 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document
January 25, 2021 Filed Jan 28, 2021 00:03 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	5,604	$0.00	$0.00	Disclosure SEC source: 0000886163-21-000015 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,875 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document
January 25, 2021 Filed Jan 28, 2021 00:03 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	1,053	$156.01	$164,278.53	Disclosure SEC source: 0000886163-21-000015 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,271 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document
January 25, 2021 Filed Jan 28, 2021 00:03 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	2,911	$0.00	$0.00	Disclosure SEC source: 0000886163-21-000015 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,324 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:40 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $5.80	$0.00	Disclosure SEC source: 0001209191-21-002128 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-01-04 Read SEC document
August 24, 2020 Filed Aug 25, 2020 23:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	78	$0.00 Strike: $21.92	$0.00	Disclosure SEC source: 0000886163-20-000099 · edgardoc.xml · derivative · entry 7 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,547 Underlying: Common Stock · 78 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 03, 2020, in accordance with Rule 10b5-1. F4 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document
August 24, 2020 Filed Aug 25, 2020 23:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	78	$110.89	$8,649.42	Disclosure SEC source: 0000886163-20-000099 · edgardoc.xml · nonDerivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,413 F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 03, 2020, in accordance with Rule 10b5-1. Read SEC document
August 24, 2020 Filed Aug 25, 2020 23:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	78	$21.92	$1,709.76	Disclosure SEC source: 0000886163-20-000099 · edgardoc.xml · nonDerivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 03, 2020, in accordance with Rule 10b5-1. Read SEC document
August 21, 2020 Filed Aug 25, 2020 23:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	790	$0.00 Strike: $74.42	$0.00	Disclosure SEC source: 0000886163-20-000099 · edgardoc.xml · derivative · entry 8 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,210 Underlying: Common Stock · 790 shares Expires 2024-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/12/14. Read SEC document
August 21, 2020 Filed Aug 25, 2020 23:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	7,225	$0.00 Strike: $14.47	$0.00	Disclosure SEC source: 0000886163-20-000099 · edgardoc.xml · derivative · entry 6 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,225 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 03, 2020, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12. Read SEC document
August 21, 2020 Filed Aug 25, 2020 23:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	7,225	$112.88	$815,540.66	Disclosure SEC source: 0000886163-20-000099 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,413 F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 03, 2020, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.26 to $114.36, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
August 21, 2020 Filed Aug 25, 2020 23:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	7,225	$14.47	$104,545.75	Disclosure SEC source: 0000886163-20-000099 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 03, 2020, in accordance with Rule 10b5-1. Read SEC document
August 21, 2020 Filed Aug 25, 2020 23:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	790	$74.42	$58,791.80	Disclosure SEC source: 0000886163-20-000099 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 30, 2020 Filed Jun 30, 2020 21:54 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	SaleCommon Stock, par value $0.00001 per share	13,000	$7.35	$95,550.00	Disclosure SEC source: 0001209191-20-039521 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Read SEC document
April 10, 2020 Filed Apr 23, 2020 20:15 UTC	FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776	Disposition to issuerWarrant Shares (right to buy) · Derivative	38,461	Not disclosed Strike: $1.30	Not disclosed	Disclosure SEC source: 0001382963-20-000084 · edgar.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,461 shares Expires 2023-11-05 F2 · shares: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended. F2 · price: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended. Read SEC document
April 10, 2020 Filed Apr 23, 2020 20:15 UTC	FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776	GrantCommon Stock	38,461	$0.00	$0.00	Disclosure SEC source: 0001382963-20-000084 · edgar.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,635 F2 · shares: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended. Read SEC document
March 13, 2020 Filed Mar 13, 2020 22:33 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,000	$0.00 Strike: $21.92	$0.00	Disclosure SEC source: 0000886163-20-000029 · edgardoc.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,625 Underlying: Common Stock · 2,000 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document
March 13, 2020 Filed Mar 13, 2020 22:33 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	2,000	$21.92	$43,840.00	Disclosure SEC source: 0000886163-20-000029 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 27, 2020 Filed Feb 28, 2020 01:35 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,706	$0.00 Strike: $21.92	$0.00	Disclosure SEC source: 0000886163-20-000027 · edgardoc.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,625 Underlying: Common Stock · 1,706 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document
February 27, 2020 Filed Feb 28, 2020 01:35 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	7,225	$0.00 Strike: $14.47	$0.00	Disclosure SEC source: 0000886163-20-000027 · edgardoc.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,225 Underlying: Common Stock · 7,225 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 15, 2019, in accordance with Rule 10b5-1. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12. Read SEC document
February 27, 2020 Filed Feb 28, 2020 01:35 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	1,706	$21.92	$37,395.52	Disclosure SEC source: 0000886163-20-000027 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 27, 2020 Filed Feb 28, 2020 01:35 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	7,225	$110.00	$794,750.00	Disclosure SEC source: 0000886163-20-000027 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,743 F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 15, 2019, in accordance with Rule 10b5-1. Read SEC document
February 27, 2020 Filed Feb 28, 2020 01:35 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	7,225	$14.47	$104,545.75	Disclosure SEC source: 0000886163-20-000027 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 15, 2019, in accordance with Rule 10b5-1. Read SEC document
February 15, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	1,170	$97.23	$113,759.10	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · nonDerivative · entry 7 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,743 F5 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document
February 15, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	447	$97.23	$43,461.81	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · nonDerivative · entry 6 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,913 F4 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document
February 15, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	869	$97.23	$84,492.87	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · nonDerivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,360 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document
February 14, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	7,225	$0.00 Strike: $14.47	$0.00	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · derivative · entry 8 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,450 Underlying: Common Stock · 7,225 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 15, 2019, in accordance with Rule 10b5-1. F6 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12. Read SEC document
February 14, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	7,225	$95.84	$692,467.12	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · nonDerivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,229 F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 15, 2019, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.45 to $96.55, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 14, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	7,225	$14.47	$104,545.75	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 15, 2019, in accordance with Rule 10b5-1. Read SEC document
February 13, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantEmployee Stock Option (right to buy) · Derivative	33,210	$0.00 Strike: $95.68	$0.00	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · derivative · entry 10 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,210 Underlying: Common Stock · 33,210 shares Expires 2030-02-13 F8 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/13/2020. Read SEC document
February 13, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	496	$0.00 Strike: $21.92	$0.00	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · derivative · entry 9 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,331 Underlying: Common Stock · 496 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document
February 13, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	7,396	$0.00	$0.00	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,229 Read SEC document
February 13, 2020 Filed Feb 18, 2020 22:09 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	496	$21.92	$10,872.32	Disclosure SEC source: 0000886163-20-000016 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 21, 2020 Filed Apr 23, 2020 20:15 UTC	FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776	ConversionSeries B convertible preferred stock · Derivative	100	$0.00 Strike: $1.30	$0.00	Disclosure SEC source: 0001382963-20-000084 · edgar.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,923 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. F1 · derivative.exercise_date: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. F1 · derivative.expiration_date: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. Read SEC document
January 21, 2020 Filed Apr 23, 2020 20:15 UTC	FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776	ConversionCommon Stock	76,923	$0.00	$0.00	Disclosure SEC source: 0001382963-20-000084 · edgar.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. Read SEC document
January 15, 2020 Filed Jan 17, 2020 23:16 UTC	FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776	GrantNon-qualified Stock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $0.23	$0.00	Disclosure SEC source: 0001382963-20-000013 · edgar.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-01-15 F1 · derivative.exercise_date: The option vests in twelve (12) equal monthly installments beginning on February 15, 2020 with the balance vesting on the 15th day of each calendar month thereafter until vested in full. Read SEC document
January 02, 2020 Filed Jan 4, 2020 00:59 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $7.95	$0.00	Disclosure SEC source: 0001209191-20-001421 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-01-02 Read SEC document
December 20, 2019 Filed Dec 26, 2019 19:01 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	1,444	$105.87	$152,876.28	Disclosure SEC source: 0000886163-19-000207 · edgardoc.xml · nonDerivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,337 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document
December 20, 2019 Filed Dec 26, 2019 19:01 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	2,913	$0.00	$0.00	Disclosure SEC source: 0000886163-19-000207 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,781 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2019. On December 20, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document
December 20, 2019 Filed Dec 26, 2019 19:01 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	2,210	$105.87	$233,972.70	Disclosure SEC source: 0000886163-19-000207 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,868 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document
December 20, 2019 Filed Dec 26, 2019 19:01 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	4,458	$0.00	$0.00	Disclosure SEC source: 0000886163-19-000207 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,078 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/29/2017 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2019. On December 20, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document
November 12, 2019 Filed Nov 13, 2019 21:07 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,001	$0.00 Strike: $21.92	$0.00	Disclosure SEC source: 0000886163-19-000201 · edgardoc.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,827 Underlying: Common Stock · 1,001 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document
November 12, 2019 Filed Nov 13, 2019 21:07 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	1,001	$21.92	$21,941.92	Disclosure SEC source: 0000886163-19-000201 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 05, 2019 Filed Sep 5, 2019 23:24 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,005	$0.00 Strike: $21.92	$0.00	Disclosure SEC source: 0000886163-19-000165 · edgardoc.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,828 Underlying: Common Stock · 1,005 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document
September 05, 2019 Filed Sep 5, 2019 23:24 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	1,005	$21.92	$22,029.60	Disclosure SEC source: 0000886163-19-000165 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 12, 2019 Filed Aug 13, 2019 17:45 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,163	$0.00 Strike: $21.92	$0.00	Disclosure SEC source: 0000886163-19-000159 · edgardoc.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,833 Underlying: Common Stock · 1,163 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document
August 12, 2019 Filed Aug 13, 2019 17:45 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	1,163	$21.92	$25,492.96	Disclosure SEC source: 0000886163-19-000159 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 11, 2019 Filed Jun 12, 2019 22:50 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,004	$0.00 Strike: $21.92	$0.00	Disclosure SEC source: 0000886163-19-000114 · edgardoc.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,996 Underlying: Common Stock · 1,004 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.